<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Inc.Hoboken pmcid: 7207162 doi: 10.15252/emmm.201910938EMMM201910938 : Article: Articles Adeno�?associated virus�?vectored" exact="influenza" post="vaccine elicits neutralizing and Fcγ receptor�?activating antibodies Daniel E"/>
 <result pre="work is properly cited.file:EMMM-12-e10938.pdf Abstract Abstract The current seasonal inactivated" exact="influenza" post="vaccine protects only against a narrow range of virus"/>
 <result pre="discovery of rare broadly protective antibodies against conserved regions in" exact="influenza" post="virus proteins has propelled research on distinct antigens and"/>
 <result pre="strains. Here, we report that adeno�?associated virus (AAV) vectors expressing" exact="influenza" post="virus HA or chimeric HA protected mice against homologous"/>
 <result pre="a rationale for further clinical development of AAV vectors as" exact="influenza" post="vaccine platform, which could benefit from their approved use"/>
 <result pre="that immunization with adeno�?associated virus vectors protects against divergent lethal" exact="influenza" post="A virus infections. Protection correlated with induction of antibodies"/>
 <result pre="adeno�?associated virus vector broadly reactive antibody FcγR HA stalk universal" exact="influenza" post="vaccine Subject Categories Immunology Microbiology, Virology &amp;amp; Host Pathogen"/>
 <result pre="also: https://doi.org/10.15252/emmm.202012059 (May 2020) The paper explained Problem Current seasonal" exact="influenza" post="vaccines show low effectiveness and protection is limited to"/>
 <result pre="within the vaccine. High morbidity and mortality caused by seasonal" exact="influenza" post="and the risk of emergence of pandemic and/or zoonotic"/>
 <result pre="broadly reactive vaccine. Results AAV vectors were used to deliver" exact="influenza" post="antigens to the lung of mice and ferrets to"/>
 <result pre="the AAV vectors are promising carriers for a broadly reactive" exact="influenza" post="vaccine. The vectored expression of the antigen was shown"/>
 <result pre="immune response toward more conserved broadly reactive epitopes within the" exact="influenza" post="virus antigens and to induce high levels of FcγR�?activating"/>
 <result pre="individuals, and has thus considerable socio�?economic impact (WHO, 2018b). Currently," exact="influenza" post="A viruses of the subtypes H1N1 and H3N2 as"/>
 <result pre="of the subtypes H1N1 and H3N2 as well as the" exact="influenza" post="B virus lineages Victoria and Yamagata circulate in humans."/>
 <result pre="surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Moreover, reassortment between" exact="influenza" post="A virus subtypes can generate even larger antigenic alterations,"/>
 <result pre="of deaths worldwide (Johnson &amp;amp; Mueller, 2002). The most recent" exact="influenza" post="pandemic was triggered by a related H1N1 virus in"/>
 <result pre="public health (Fineberg, 2014). Currently, the most effective prophylaxis against" exact="influenza" post="is immunization with trivalent or quadrivalent influenza vaccines, most"/>
 <result pre="effective prophylaxis against influenza is immunization with trivalent or quadrivalent" exact="influenza" post="vaccines, most of which contain inactivated antigenic components of"/>
 <result pre="most of which contain inactivated antigenic components of current seasonal" exact="influenza" post="A and B viruses. However, protection is mainly virus"/>
 <result pre="strains is generally poor. Although a more broadly reactive live�?attenuated" exact="influenza" post="vaccine (LAIV) is available for children, its usefulness is"/>
 <result pre="limited in adults due to pre�?existing immunity against previously encountered" exact="influenza" post="viruses (Belshe et al, 2000). The majority of vaccine"/>
 <result pre="vaccine mismatch and loss of effectiveness if the actually circulating" exact="influenza" post="viruses represent drift variants of the vaccine strains (Rondy"/>
 <result pre="variants of the vaccine strains (Rondy et al, 2017). Seasonal" exact="influenza" post="vaccination also does not provide protection against shifted or"/>
 <result pre="also does not provide protection against shifted or emerging zoonotic" exact="influenza" post="A virus strains, e.g., H5N1 or H7N9, which can"/>
 <result pre="cellular cytotoxicity (ADCC) (DiLillo et al, 2014). Vaccination with inactivated" exact="influenza" post="antigen alone is not able to efficiently induce ADCC�?activating"/>
 <result pre="However, adeno�?associated virus (AAV) vectors might be particularly suited as" exact="influenza" post="vaccine carrier, since AAV is naturally replication�?incompetent and apathogenic"/>
 <result pre="expressing internal (nucleoprotein (NP), matrix protein 1) and surface (HA)" exact="influenza" post="virus antigens protected mice from challenge infection (Xin et"/>
 <result pre="neutralizing antibodies against heterologous HA, the protection against a non�?matched" exact="influenza" post="virus observed in that study was attributed to the"/>
 <result pre="to the ferret model, thought to most accurately represent human" exact="influenza" post="disease (Enkirch &amp;amp; von Messling, 2015). A detailed knowledge"/>
 <result pre="in vitro We evaluated the potency of AAV vectors expressing" exact="influenza" post="virus wild�?type HA and NP, or cHA and headless"/>
 <result pre="cHA and headless HA antigens to confer broad protection from" exact="influenza" post="virus challenge in comparison with an inactivated vaccine (Fig"/>
 <result pre="constructs were based on proteins encoded by the prototypic pandemic" exact="influenza" post="virus A/California/7/2009 (H1N1)pdm (Cal/7/9) (Fig 1B). The cHA contained"/>
 <result pre="the stalk region of Cal/7/9 and head regions derived from" exact="influenza" post="A virus subtypes H2 (cHA1), H10 (cHA2), or H13"/>
 <result pre="were detected by immune sera raised against the respective parental" exact="influenza" post="virus HA subtype, i.e., H2, H10, or H13, indicating"/>
 <result pre="nostrils three times in 3�?week intervals before being challenged with" exact="influenza" post="viruses. Control groups received either three times AAV�?GFP or"/>
 <result pre="samples were taken at indicated time points (red drops). After" exact="influenza" post="challenge, mice were monitored for survival and weight loss"/>
 <result pre="of serum antibodies was tested against a panel of ten" exact="influenza" post="viruses from both antigenic group 1 (H1N1, H2N3, H5N1,"/>
 <result pre="AAV�?NP and WIV immunization led to antibody responses reacting with" exact="influenza" post="A viruses from both antigenic groups. Broadly reactive HA�?specific"/>
 <result pre="four different H1N1 viruses spanning more than 90 years of" exact="influenza" post="virus evolution (Fig EV2A). HA1 contains the head region,"/>
 <result pre="against all viral proteins. MDCKII cells were either infected with" exact="influenza" post="virus before pre�?challenge sera and FcγR�?reporter cells were added."/>
 <result pre="cell, which is quantified by anti�?IL�?2 ELISA. BCorrelation between total" exact="influenza" post="IgG ELISA titers and FcγR�?activating antibody titers against PR8"/>
 <result pre="WIV and then challenged with a lethal dose of homologous" exact="influenza" post="virus (Cal/7/9) (A, B; n = 5) or two"/>
 <result pre="of WIV in reducing mortality and disease severity against heterologous" exact="influenza" post="challenge in mice. AAV�?vectored vaccines reduce disease severity in"/>
 <result pre="ferrets, as they most closely reproduce the course of human" exact="influenza" post="(Enkirch &amp;amp; von Messling, 2015). While focusing on HA�?based"/>
 <result pre="one group was given two doses of the commercial quadrivalent" exact="influenza" post="vaccine (QIV) of season 2017/18 by the intramuscular route."/>
 <result pre="(WHO, 2018c). All animals except for the AAV�?GFP group developed" exact="influenza" post="virus�?specific antibodies (Fig 6B). However, a statistically significant continuous"/>
 <result pre="(H) with an anti�?H1N1 polyclonal antibody (bar: 100 μm; red:" exact="influenza" post="antigen (Neufuchsin); blue: nuclei (hematoxylin)). I, JH&amp;amp;E�?stained histological sections"/>
 <result pre="the linear regression curve. F, GScoring of IHC staining of" exact="influenza" post="A virus antigen expression in submucosal glands (SMG) or"/>
 <result pre="al, 2012). During the 3�?day challenge period, clinical signs of" exact="influenza" post="were monitored, and weight and temperature were measured. At"/>
 <result pre="histopathological examination (Fig 6A). All animals developed classical signs of" exact="influenza" post="disease starting on day 1, including serous nasal exudate,"/>
 <result pre="titers in the nasal turbinates (Fig EV5E). Immunohistochemical staining detected" exact="influenza" post="virus antigen in the lungs of all animals yet"/>
 <result pre="6G and H). Also, all ferrets developed signs of an" exact="influenza" post="virus�?induced bronchio�?interstitial pneumonia, although at varying degrees. Damage of"/>
 <result pre="AAV�?HA and AAV�?cHA immunization reduced the disease severity after homologous" exact="influenza" post="virus infection in ferrets. However, only with AAV�?HA this"/>
 <result pre="important element on the quest for a universal and long�?lasting" exact="influenza" post="vaccine (Erbelding et al, 2018; Ortiz et al, 2018)."/>
 <result pre="2018). Commonly used viral vectors have proven their efficacy as" exact="influenza" post="vaccine carriers in multiple studies (de Vries &amp;amp; Rimmelzwaan,"/>
 <result pre="immune response to HA within the same antigenic group of" exact="influenza" post="A viruses (Krammer et al, 2013; Margine et al,"/>
 <result pre="immunization induced a remarkably broad antibody response covering all tested" exact="influenza" post="viruses and capable to activate FcγR, despite the fact"/>
 <result pre="to a study where vaccination with different cHA expressed by" exact="influenza" post="B�?, VSV�?, or AdV vectors reduced viral titers (Krammer"/>
 <result pre="memory, or to boost and maintain such a response in" exact="influenza" post="experienced individuals (Andrews et al, 2015). In conclusion, the"/>
 <result pre="of AAV vectors into a carrier for a broadly protective" exact="influenza" post="vaccine. Materials and Methods AAV vector design and production"/>
 <result pre="of the head regions, i.e., regions cysteine52–cysteine277, derived from of" exact="avian influenza" post="A viruses of the subtypes H2, H10, or H13"/>
 <result pre="the head regions, i.e., regions cysteine52–cysteine277, derived from of avian" exact="influenza" post="A viruses of the subtypes H2, H10, or H13"/>
 <result pre="amounts of AAV vector genomes per microliter. Cell lines and" exact="influenza" post="viruses 293T were maintained in DMEM, and MDCKII cells"/>
 <result pre="unit 17 and tested negative for mycoplasma contamination. Infections with" exact="influenza" post="viruses were performed in cell culture medium with 0.2%"/>
 <result pre="M145; TaKaRa, Kusatsu, Japan) antibody, rabbit hyperimmune serum against the" exact="influenza" post="subtypes H2, H10, and H13 (1:500; 11688�?RP01�?100, 11693�?RP01�?100, 11721�?RP01�?100"/>
 <result pre="GAPDH antibody (1:1,000) staining. 4–8 μg per lane of sucrose�?purified" exact="influenza" post="viruses was separated on SDS–PAGE under denaturing conditions and"/>
 <result pre="plates (Thermo Fischer Scientific) were coated with 4–8 μg/ml purified" exact="influenza" post="virus or approximately 1 × 1010 vg/ml AAV9 empty"/>
 <result pre="plates (Thermo Fischer Scientific) were coated with 4–8 μg/ml purified" exact="influenza" post="virus in 50 μl carbonate/bicarbonate buffer (pH = 9.6)"/>
 <result pre="2015) with the exception that 3.5 × 104 PFU of" exact="influenza" post="virus was used per 96 well to examine mouse"/>
 <result pre="102 PFU per 96 well for ferret sera. Detection of" exact="influenza" post="antigen was done with anti�?influenza A polyclonal antibody (1:1,000;"/>
 <result pre="were dilutions of 1:100 (for AAV MN), 1:40 (for mouse" exact="influenza" post="MN), and 1:10 (for ferret influenza MN), respectively. Hemagglutinin"/>
 <result pre="MN), 1:40 (for mouse influenza MN), and 1:10 (for ferret" exact="influenza" post="MN), respectively. Hemagglutinin inhibition (HAI) Animal sera were inactivated"/>
 <result pre="μl per 96�?well. Four HAU per 25 μl PBS of" exact="influenza" post="virus were added to each well, and samples were"/>
 <result pre="normalized to negative control serum (AAV�?GFP). FcγR assay To display" exact="influenza" post="virus surface antigens on MDCKII cells, cells were seeded"/>
 <result pre="cells were seeded into 96�?well plates and either infected with" exact="influenza" post="virus (3.5 × 103 PFU per well) or transfected"/>
 <result pre="a single AAV�?GFP�?immunized animal, which survived without weight loss, remained" exact="influenza" post="virus seronegative, indicating that the inoculum was not taken"/>
 <result pre="of the Paul�?Ehrlich�?Institute (Langen, Germany) and tested seronegative for circulating" exact="influenza" post="viruses prior to the experiment. Ferrets were anesthetized by"/>
 <result pre="4�?week intervals. One human dose per ferret of quadrivalent inactivated" exact="influenza" post="vaccine of season 2017/18 containing 15 μg HA per"/>
 <result pre="of pathologic lesions using lung�?specific inflammation score parameters for quantifying" exact="influenza" post="virus�?induced pneumonia as described (Dietert et al, 2017). These"/>
 <result pre="lesions using lung�?specific inflammation score parameters for quantifying influenza virus�?induced" exact="pneumonia" post="as described (Dietert et al, 2017). These parameters included"/>
 <result pre="et al, 2017). These parameters included severity of (i) interstitial" exact="pneumonia" post="with infiltration by macrophages, lymphocytes, neutrophils (ii) bronchitis, (iii)"/>
 <result pre="(v) hyperplasia of type II pneumocytes. For immunohistochemical detection of" exact="influenza" post="A virus, heat�?mediated antigen retrieval was performed in 10"/>
 <result pre="for 12 min. Lung sections were incubated with a polyclonal" exact="influenza" post="A H1N1 antibody (1:250; 5315�?0064, AbD Serotec, Puchheim, Germany)"/>
 <result pre="for histopathological and immunohistochemical analysis. Neither one of the above�?mentioned" exact="influenza" post="infection�?specific parameter nor influenza virus antigen could be detected"/>
 <result pre="analysis. Neither one of the above�?mentioned influenza infection�?specific parameter nor" exact="influenza" post="virus antigen could be detected in these control samples."/>
 <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virus. Clin Vaccine Immunol21: 1528–153325209558 AlamS, KnowldenZAG, SangsterMY, SantAJ"/>
 <result pre="limiting and selective during the primary B cell response to" exact="influenza" post="virus infection. J Virol88: 314–32424155379 AltmanMO, BenninkJR, YewdellJW, HerrinBR"/>
 <result pre="314–32424155379 AltmanMO, BenninkJR, YewdellJW, HerrinBR (2015) Lamprey VLRB response to" exact="influenza" post="virus supports universal rules of immunogenicity and antigenicity. Elife4:"/>
 <result pre="HasegawaH, SatoY, ShimadaS, NannoM, MatsuokaY, OhwakiMet al (2002) Protection against" exact="influenza" post="virus infection in polymeric Ig receptor knockout mice immunized"/>
 <result pre="2930–293811884464 BalazsAB, BloomJD, HongCM, RaoDS, BaltimoreD (2013) Broad protection against" exact="influenza" post="infection by vectored immunoprophylaxis in mice. Nat Biotechnol31: 647–65223728362"/>
 <result pre="KentSJ, GilchukPet al (2019) A site of vulnerability on the" exact="influenza" post="virus hemagglutinin head domain trimer interface. Cell177: 1136–1152 e1831100268"/>
 <result pre="(2000) Efficacy of vaccination with live attenuated, cold�?adapted, trivalent, intranasal" exact="influenza" post="virus vaccine against a variant (A/Sydney) not contained in"/>
 <result pre="(2019) Cross�?protective potential and protection�?relevant immune mechanisms of whole inactivated" exact="influenza" post="virus vaccines are determined by adjuvants and route of"/>
 <result pre="immunological significance of a human monoclonal antibody directed to the" exact="influenza" post="a virus nucleoprotein. Clin Vaccine Immunol20: 1333–133723761662 BournazosS, RavetchJV"/>
 <result pre="KorseHJWM, KwaksT, OtterstromJJ, JuraszekJet al (2013) Mechanisms of hemagglutinin targeted" exact="influenza" post="virus neutralization. PLoS One8: e8003424348996 BuningH, SchmidtM (2015) Adeno�?associated"/>
 <result pre="role for non�?neutralizing antibodies against nucleoprotein in facilitating resistance to" exact="influenza" post="virus. J Immunol181: 4168–417618768874 CatonAJ, BrownleeGG, YewdellJW, GerhardW (1982)"/>
 <result pre="CatonAJ, BrownleeGG, YewdellJW, GerhardW (1982) The antigenic structure of the" exact="influenza" post="virus A/PR/8/34 hemagglutinin (H1 subtype). Cell31: 417–4276186384 Corrales�?AguilarE, TrillingM,"/>
 <result pre="neutralizing hemagglutinin stalk�?specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivo. Nat Med20: 143–15124412922 DiLilloDJ, PaleseP, WilsonPC,"/>
 <result pre="CarnellG, TempertonNet al (2018) Cross�?protective immune responses induced by sequential" exact="influenza" post="virus infection and by sequential vaccination with inactivated influenza"/>
 <result pre="sequential influenza virus infection and by sequential vaccination with inactivated" exact="influenza" post="vaccines. Front Immunol9: 231230356772 EkiertDC, FriesenRHE, BhabhaG, KwaksT, JongeneelenM,"/>
 <result pre="al (2011) A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science (New York, NY)333: 843–850 EllebedyAH, KrammerF,"/>
 <result pre="al (2014) Induction of broadly cross�?reactive antibody responses to the" exact="influenza" post="HA stem region following H5N1 vaccination in humans. Proc"/>
 <result pre="StemmyEJ, RobertsPC, AugustineAD, FergusonS, PaulesCI, GrahamBS, FauciAS (2018) A universal" exact="influenza" post="vaccine: the strategic plan for the national institute of"/>
 <result pre="influenza vaccine: the strategic plan for the national institute of" exact="allergy" post="and infectious diseases. J Infect Dis218: 347–35429506129 collab: FDA"/>
 <result pre="(2014) Pandemic preparedness and response – lessons from the H1N1" exact="influenza" post="of 2009. N Engl J Med370: 1335–134224693893 FriesenRH, LeePS,"/>
 <result pre="KoudstaalW, JongeneelenMet al (2014) A common solution to group 2" exact="influenza" post="virus neutralization. Proc Natl Acad Sci USA111: 445–45024335589 GaoG,"/>
 <result pre="J Virol78: 6381–638815163731 GerdilC (2003) The annual production cycle for" exact="influenza" post="vaccine. Vaccine21: 1776–177912686093 GrimmD, BuningH (2017) Small but increasingly"/>
 <result pre="5774–578122398287 HeW, MullarkeyCE, MillerMS (2015) Measuring the neutralization potency of" exact="influenza" post="A virus hemagglutinin stalk/stem�?binding antibodies in polyclonal preparations by"/>
 <result pre="(2017) Alveolar macrophages are critical for broadly�?reactive antibody�?mediated protection against" exact="influenza" post="A virus in mice. Nat Commun8: 84629018261 Henry DunandCJ,"/>
 <result pre="HirshA, ZhengNYet al (2016) Both neutralizing and non�?neutralizing human H7N9" exact="influenza" post="vaccine�?induced monoclonal antibodies confer protection. Cell Host Microbe19: 800–81327281570"/>
 <result pre="EhrlichHJet al (2011) Vectors based on modified vaccinia ankara expressing" exact="influenza" post="H5N1 hemagglutinin induce substantial cross�?clade protective immunity. PLoS One6:"/>
 <result pre="SchwendingerMG, PilzA, BarrettPN, FalknerFGet al (2014) MVA vectors expressing conserved" exact="influenza" post="proteins protect mice against lethal challenge with H5N1, H9N2"/>
 <result pre="van MeersbergenR, HuizinghJ, WanningenP, VerspuijJet al (2015) A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science (New"/>
 <result pre="ButlerJ, ParsonsMS, AlcantaraS, PetravicJ, DavenportMP, HurtACet al (2013) Standard trivalent" exact="influenza" post="virus protein vaccination does not prime antibody�?dependent cellular cytotoxicity"/>
 <result pre="WrightPF, TreanorJ, RosenbergerCMet al (2016) Generation and protective ability of" exact="influenza" post="virus�?specific antibody�?dependent cellular cytotoxicity in humans elicited by vaccination,"/>
 <result pre="(2002) Updating the accounts: global mortality of the 1918�?1920 &quot;Spanish�?" exact="influenza" post="pandemic. Bull Hist Med76: 105–11511875246 KrammerF, PicaN, HaiR, MargineI,"/>
 <result pre="Med76: 105–11511875246 KrammerF, PicaN, HaiR, MargineI, PaleseP (2013) Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk�?specific antibodies. J"/>
 <result pre="Leyva�?GradoVH, RyderAB, MillerMS, RoseJK, PaleseP, García�?SastreAet al (2014) Assessment of" exact="influenza" post="virus hemagglutinin stalk�?based immunity in ferrets. J Virol88: 3432–344224403585"/>
 <result pre="MontoAS (2018) NAction! How can neuraminidase�?based immunity contribute to better" exact="influenza" post="virus vaccines?mBio9: e02332�?17 LaursenNS, FriesenRHE, ZhuX, JongeneelenM, BloklandS, VermondJ,"/>
 <result pre="EijgenA, TangC, van DiepenH, ObmolovaGet al (2018) Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutinin. Science"/>
 <result pre="Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutinin. Science (New York, NY)362: 598–602 LeonPE, HeW, MullarkeyCE,"/>
 <result pre="PaleseP, TanGS (2016) Optimal activation of Fc�?mediated effector functions by" exact="influenza" post="virus hemagglutinin antibodies requires two points of contact. Proc"/>
 <result pre="AndrewsSF, ZhengNY, LeeJH, HuangM, QuX, EdupugantiSet al (2012) Pandemic H1N1" exact="influenza" post="vaccine induces a recall response in humans that favors"/>
 <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9. Clin Vaccine Immunol20: 1836–183724132603 LinJ, CalcedoR,"/>
 <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9. Clin Vaccine Immunol20: 1836–183724132603 LinJ, CalcedoR,"/>
 <result pre="immunization with live�?attenuated chimeric hemagglutinin�?based vaccines confers heterosubtypic immunity against" exact="influenza" post="a viruses in a preclinical ferret model. Front Immunol10:"/>
 <result pre="(2013) Hemagglutinin stalk�?based universal vaccine constructs protect against group 2" exact="influenza" post="A viruses. J Virol87: 10435–1044623903831 MedinaRA, ManicassamyB, StertzS, SeibertCW,"/>
 <result pre="Garcia�?SastreA (2010) Pandemic 2009 H1N1 vaccine protects against 1918 Spanish" exact="influenza" post="virus. Nat Commun1: 2820975689 MelianiA, LeborgneC, TriffaultS, Jeanson�?LehL, VeronP,"/>
 <result pre="RoseJK, PaleseP, Garcia�?SastreA, KrammerF, AlbrechtRA (2015) Hemagglutinin stalk immunity reduces" exact="influenza" post="virus replication and transmission in ferrets. J Virol90: 3268–327326719251"/>
 <result pre="AtlasT, RajendranM, SolorzanoA, Berlanda�?ScorzaF, Garcia�?SastreA, PalesePet al (2017) A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
 <result pre="(1993) A common neutralizing epitope conserved between the hemagglutinins of" exact="influenza" post="A virus H1 and H2 strains. J Virol67: 2552–25587682624"/>
 <result pre="al (2018) Report on eighth WHO meeting on development of" exact="influenza" post="vaccines that induce broadly protective and long�?lasting immune responses:"/>
 <result pre="RondyM, El OmeiriN, ThompsonMG, LevequeA, MorenA, SullivanSG (2017) Effectiveness of" exact="influenza" post="vaccines in preventing severe influenza illness among adults: a"/>
 <result pre="MorenA, SullivanSG (2017) Effectiveness of influenza vaccines in preventing severe" exact="influenza" post="illness among adults: a systematic review and meta�?analysis of"/>
 <result pre="RyderAB, NachbagauerR, BuonocoreL, PaleseP, KrammerF, RoseJK (2015) Vaccination with vesicular" exact="stomatitis" post="virus�?vectored chimeric hemagglutinins protects mice against divergent influenza virus"/>
 <result pre="with vesicular stomatitis virus�?vectored chimeric hemagglutinins protects mice against divergent" exact="influenza" post="virus challenge strains. J Virol90: 2544–255026676789 SipoI, KnaufM, FechnerH,"/>
 <result pre="recombinant AAV vectors expressing codon�?optimized genes from pandemic swine origin" exact="influenza" post="virus (SOIV). Vaccine29: 1690–169921195079 SonntagF, KotherK, SchmidtK, WeghoferM, RauppC,"/>
 <result pre="(2016) Broadly�?reactive neutralizing and non�?neutralizing antibodies directed against the H7" exact="influenza" post="virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog12:"/>
 <result pre="(2018) Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting" exact="influenza" post="HA�?stem. J Clin Invest29: 850–862 TrippRA, TompkinsSM (2014) Virus�?vectored"/>
 <result pre="influenza HA�?stem. J Clin Invest29: 850–862 TrippRA, TompkinsSM (2014) Virus�?vectored" exact="influenza" post="virus vaccines. Viruses6: 3055–307925105278 Van den HoeckeS, EhrhardtK, KolpeA,"/>
 <result pre="Hierarchical and redundant roles of activating FcgammaRs in protection against" exact="influenza" post="disease by M2e�?specific IgG1 and IgG2a antibodies. J Virol129:"/>
 <result pre="antibody dependent natural killer cell activation by antibodies to internal" exact="influenza" post="virus proteins. EBioMedicine8: 277–29027428437 de VriesRD, RimmelzwaanGF (2016) Viral"/>
 <result pre="virus proteins. EBioMedicine8: 277–29027428437 de VriesRD, RimmelzwaanGF (2016) Viral vector�?based" exact="influenza" post="vaccines. Hum Vaccin Immunother12: 2881–290127455345 WalzL, KaysSK, ZimmerG, von"/>
 <result pre="MesslingV (2018) Sialidase�?inhibiting antibody titers correlate with protection from heterologous" exact="influenza" post="virus strains of the same neuraminidase subtype. J Virol92:"/>
 <result pre="(2015) Anti�?HA glycoforms drive B cell affinity selection and determine" exact="influenza" post="vaccine efficacy. Cell162: 160–16926140596 WatanabeA, McCarthyKR, KuraokaM, SchmidtAG, AdachiY,"/>
 <result pre="TonouchiK, CaradonnaTM, BajicG, SongSet al (2019) Antibodies to a conserved" exact="influenza" post="head interface epitope protect by an IgG subtype�?dependent mechanism."/>
 <result pre="mechanism. Cell177: 1124–1135 e1631100267 collab: WHO (2002) Manual on animal" exact="influenza" post="diagnosis and surveillance In WHO global influenza programme, WebsterR,"/>
 <result pre="Manual on animal influenza diagnosis and surveillance In WHO global" exact="influenza" post="programme, WebsterR, CoxN, StöhrK (eds), pp 77�?79. Geneva, Switzerland:"/>
 <result pre="collab: WHO (2018a) Cumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018 In Cumulative number of"/>
 <result pre="WHO (2018a) Cumulative number of confirmed human cases for avian" exact="influenza" post="A(H5N1) reported to WHO, 2003–2018 In Cumulative number of"/>
 <result pre="WHO, 2003–2018 In Cumulative number of confirmed human cases for" exact="avian influenza." post="Geneva, Switzerland: World Health Organizationhttps://www.who.int/influenza/human_animal_interface/2018_03_02_tableH5N1.pdf collab: WHO (2018b) Influenza"/>
 <result pre="Health Organizationhttps://www.who.int/influenza/human_animal_interface/2018_03_02_tableH5N1.pdf collab: WHO (2018b) Influenza (Seasonal) fact sheet on" exact="influenza" post="no. 211 In Fact sheet on influenza no 211."/>
 <result pre="fact sheet on influenza no. 211 In Fact sheet on" exact="influenza" post="no 211. Geneva, Switzerland: World Health Organizationhttps://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) collab: WHO"/>
 <result pre="Organizationhttps://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) collab: WHO (2018c) WHO recommendations on the composition of" exact="influenza" post="virus vaccines In Recommendations on the composition of influenza"/>
 <result pre="of influenza virus vaccines In Recommendations on the composition of" exact="influenza" post="virus vaccines. Geneva, Switzerland: World Health Organizationhttps://www.who.int/influenza/vaccines/virus/recommendations/en/ WohlboldTJ, NachbagauerR,"/>
 <result pre="with soluble headless hemagglutinin protects mice from challenge with divergent" exact="influenza" post="viruses. Vaccine33: 3314–332126026378 WuNC, WilsonIA (2017) A perspective on"/>
 <result pre="the structural and functional constraints for immune evasion: insights from" exact="influenza" post="virus. J Mol Biol429: 2694–270928648617 XinKQ, UrabeM, YangJ, NomiyamaK,"/>
 <result pre="GallagherJR, WangL, ZhangY, JoyceMGet al (2015) Hemagglutinin�?stem nanoparticles generate heterosubtypic" exact="influenza" post="protection. Nat Med21: 1065–107026301691 YuX, TsibaneT, McGrawPA, HouseFS, KeeferCJ,"/>
 <result pre="(2008) Neutralizing antibodies derived from the B cells of 1918" exact="influenza" post="pandemic survivors. Nature455: 532–53618716625"/>
</results>
